TX-PLANVIEW
23.2.2021 15:03:16 CET | Business Wire | Press release
Planview, a global leader in Portfolio Management and Work Management solutions, today announced it has closed its previously announced acquisitions of Clarizen and Changepoint, two leading Project Portfolio Management (PPM) providers.
“For more than three decades, Planview has been pioneering the technologies and best practices that the world’s best companies use to reimagine the ways they plan and manage work,” said Greg Gilmore, CEO of Planview. “Together, Planview, Clarizen, and Changepoint offer a portfolio for the modern enterprise, providing organizations the visibility and agility needed to drive more innovation, execute on their strategic objectives, and capitalize on compelling opportunities. We are thrilled to welcome Clarizen and Changepoint into the extended Planview family.”
As a result of the transaction, Planview, Clarizen and Changepoint customers will benefit from being part of a premier community of PMOs, PPM, and Professional Services Automation (PSA) practitioners. The expanded portfolio of solutions will provide customers the tools and resources to better strategically plan and deliver on their most important initiatives. The combination will be transformative for the industry and has received strong feedback from customers to date.
The nature of work has changed significantly in recent years, causing leaders across industries to rethink how to best strategically plan, execute, and empower teams in today’s all-digital world. This shift has placed a spotlight on the growing importance and strategic value of Portfolio Management, Work Management and Enterprise Agile Planning capabilities, as evidenced by the recent wave of IPOs, consolidation, and acquisitions of several key players in this category. Planview’s rich history in the space, acquisitions of Clarizen and Changepoint, its comprehensive product offerings, and its significant growth position have placed the company at the forefront of this global market.
“This acceleration of PPM and work management acquisitions indicates the vital need for companies to adapt and manage the way they work in the face of fast changes to the global economy and competitive landscapes,” said Melinda Ballou, Research Director, Agile ALM, Quality & Portfolio Strategies at IDC. “The need to respond adaptively and collaboratively to unexpected change will endure. This dual acquisition on the part of Planview is a bold move to scale the company in several related and growing market areas, and with effective integration and alignment, we would expect more strategic positioning for Planview moving forward.”
The close of the transactions closely follows Planview’s acquisition in December 2020 by TPG Capital and TA Associates, whose investment has focused on accelerating Planview’s growth and vision for Agile and PPM for Enterprises. Clarizen and Changepoint are the company’s largest acquisitions to date and represent an important first step in Planview’s growth strategy for 2021.
Planview is also coming off of its strongest financial year in company history, capped by a fourth quarter that included its largest customer deal and most successful financial quarter on record, as well as a significant uptick in customer adoption of Planview’s Lean and Agile Delivery solutions. To learn more, visit: www.planview.com .
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: the Planview website at www.planview.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005335/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
